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Abstract 
CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) is a useful enzyme target for a range of medical 
conditions including cancer, cardiovascular and autoimmune disease, which show elevated CYP24A1 
levels and corresponding reduction of calcitriol (the biologically active form of vitamin D). A series of 
(E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides have been synthesised 
using an efficient synthetic route and shown to be potent inhibitors of CYP24A1 (IC50 0.11-
0.35 M) compared with the standard ketoconazole. Molecular modelling using our CYP24A1 
homology model showed the inhibitors to fill the hydrophobic binding site, forming key 
transition metal interaction between the imidazole nitrogen and the haem Fe3+ and multiple 
interactions with the active site amino acid residues. 
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1. Introduction 
Vitamin D is the starting compound of an endocrine system, and plays a principal role in the 
maintenance of calcium and phosphate homeostasis and is essential for the maintenance of a 
healthy skeleton1. Vitamin D is produced in the epidermis from 7-dehydrocholestrol, by 
sunlight or UV light. Vitamin D can also be obtained from dietary sources. Previtamin D3  is 
produced by the opening of the steroid nucleus (B ring broken by UV light with spectrum 280 
- 320 UV β)2. Previtamin D3 isomerises into Vitamin D33. Additionally the three most important 
steps in vitamin D metabolism, 25-hydroxylation, 1ߙ-hydroxylation, and 24-hydroxylation are 
all performed by cytochrome P450 enzymes4.  
 
Figure 1. Metabolic pathway of Vitamin D 
The initial step in vitamin D metabolism is 25 hydroxylation (endoplasmic reticulum) by 
CYP2R1 (25-hydroxylase), found in the liver to produce 25(OH)D3 (the circulatory form of 
UVB
Skin
7- Dehydrocholesterol Previtamin D Vitamin D3
Complex with binding 
protein in liver
CYP2R liver
25- hydroxyvitamin D3
Renal tubles
Calcitriol
Degradation CYP24A1
Calcitroic acid
inactive
Excreted in urine
PTH
CYP27B1
= stimulate the action
= inhibit the action
4 
 
vitamin D)
 (Figure 1)2. 1,25(OH)2D3  (calcitriol), the active form of vitamin D, is produced in 
the renal distal convoluted tubule at position 1α by CYP27B1 a cytochrome P450 
monooxygenase which helps many reactions involved in drug metabolism and the synthesis of 
cholesterol, steroids, and other lipids5.  CYP27B1 is stimulated by parathyroid hormone (PTH) 
and is indirectly deactivated by fibroblast growth factor (FGF-23) (Figure 1)6. 
The main function of calcitriol is mineralisation of the skeleton and maintaining levels of 
calcium7,8. However, calcitriol also plays a role in many other organs with vitamin D deficiency 
linked to chronic kidney disease9,10, cardiovascular disease11,12, autoimmune disease13,14 and 
cancer15,16,17,18,19. Reduction in calcitriol levels is linked with increased CYP24A1 levels, 
which suggests that CYP24A1 may be a useful therapeutic target20. Many cancer cell lines 
display elevated levels of CYP24A1 expression as they progress to more tumourigenic 
phenotypes, suggesting that these tumours have increased ability to catabolise calcitriol. 
Subsequently, several CYP24A1 inhibitors have been designed for the treatment of diseases 
associated with elevated vitamin D catabolism. Azole-based compounds can inactivate a broad 
range of cytochrome P450 enzymes by binding to the haem moiety present in the enzyme active 
site. Through the coordination of the azole nitrogen to the haem, it blocks the catalytic cycle 
of the P450 and prevents oxygen activation required for substrate oxidation. Despite their lack 
of specificity towards just CYP24A1, ketoconazole and liarazole were shown to extend the 
half-life of calcitriol in prostate cancer cells in vitro and in vivo21. We have previously described 
azole CYP24A1 inhibitors22,23,24,25, of these the styrylimidazole series24 was the most 
promising with potent CYP24A1 inhibitory activity observed (Figure 2).The aim of this 
research was the design and synthesis of novel potent inhibitors of CYP24A1 to enhance the 
endogenous levels of circulating calcitriol. 
5 
 
 
Figure 2. Lead styrylimidazoles and designed inhibitors 
 
The lead styrylimidazoles (Figure 2) have been modified and developed, specifically 
through (i) substitution of the phenyl ring on the imidazole side to explore structure 
activity-relationships; (ii) substitution of the styrene benzene rings to explore structure 
activity-relationships and (iii) variation of the alkene position to allow complete filling of 
the CYP24A1 active site. 
 
2. Results and Discussion 
 
2.1 Chemistry 
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Both the 4- and 3-substituted final compounds, (E)-N-(2-(1H-imidazol-1-yl)-2-(phenyl)ethyl)-4-
styrylbenzamides (9) and  (E)-N-(2-(1H-imidazol-1-yl)-2-(phenyl)ethyl)-3-styrylbenzamides (15), 
were obtained in an efficient three step synthesis from the precursor styrylbenzoic acids and 2-amino-
1-phenylethanol derivatives. 
2.1.1. Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenyl)ethyl)-4-styrylbenzamides 
The extension of the (E)-N-(2-(1H-imidazol-1-yl)-2-(phenyl)ethyl)-4-styrylbenzamide series 
required coupling of the appropriate 2-amino-1-phenylethanol (5) with a 4-styrylbenzoic acid 
(8). The  2-amino-1-phenylethanol derivatives (5) were prepared in two steps, first the ߚ-
nitroalcohols (4) were prepared from the corresponding benzaldehyde (3) and nitromethane by 
the Henry reaction employing either NaOH, Amberseep 900 (OH) or triethylamine as the 
base26,27,28. Reduction of the ߚ-nitroalcohols to the corresponding amino derivatives (5) was 
achieved using a slurry of Raney nickel and formic acid under H2 atmosphere at room 
temperature for 6 h (Scheme 1)29. The 4-styrylbenzoic acids (8) were conveniently prepared 
from the corresponding alkene (6) and 4-bromobenzoic acid (7) under Heck reaction conditions 
(Scheme 1). 
 
Scheme 1. Reagents and conditions: (i) Method A CH3NO2, MeOH, NaOH, 0 oC, 24 h; Method 
B CH3NO2, Ambersep 900 (OH), rt, o/n; Method C CH3NO2, Et3N, rt, 12 h (ii)  Raney Ni/H2, 
MeOH, HCO2H, rt, 6 h (iii) Pd(OAc)2, tri(o-tolylphosphine), Et3N, 100 oC, o/n. 
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Coupling of the appropriate 2-amino-1-phenylethanol (5) with a 4-styrylbenzoic acid (8) using 
CDI as the coupling reagent gave the benzamides (9). The dihydrooxazoles (10) were prepared 
following the procedure of Aboraia et al23 and involved the formation of the 1,3-oxazole ring 
by reacting benzamide (9) with methansulfonyl chloride and triethylamine in dry THF. In the 
last step of the reaction scheme, heating the oxazole compound (10) in the presence of 
imidazole for 48 h at 125 oC opened the oxazole ring by nucleophilic displacement (Scheme 
2)24. A reasonable yield of the imidazole compounds (11) was produced after recrystallisation 
from ethylacetate or acetonitrile (Table 1).  
 
Scheme 2. Reagents and conditions: (i) Carbonyldiimidazole, DMF, rt, o/n (ii)  (a) CH3SO2Cl, 
THF, 0 oC, 3 h (b)  Et3N, rt, o/n (iii) imidazole, 125 oC, 48 h. 
 
2.1.2. Synthesis of (E)-N-(2-(1H-imidazol-1-yl)-2-(phenyl)ethyl)-3-styrylbenzamides 
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In a similar manner the (E)-N-(2-(1H-imidazol-1-yl)-2-(phenyl)ethyl)-3-styrylbenzamide series (17) 
were prepared in moderate yields (Table 1) from the appropriate 3-styrylbenzoic acid (14) and 
2-amino-1-phenylethanol (5) (Scheme 3). 
 
 
Scheme 3. Reagents and conditions: (i) Pd(OAc)2, tri(o-tolylphosphine), Et3N, 100 oC, o/n (ii) 
Carbonyldiimidazole, DMF, rt, o/n (iii)  (a) CH3SO2Cl, THF, 0 oC, 3 h (b)  Et3N, rt, o/n (iv) 
imidazole, 125 oC, 48 h. 
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Table 1. Substitutions, yields and melting points of final imidazole products 
Cmpd R R1 R2 R3 Yield (%) Mp (oC) 
11a 4-Cl H H - 12 238-240 
11b 4-CF3 H H - 33 208-210 
11c 2-CF3 H H - 35 174-178 
11d 3,4-diMe H H - 27 134-136 
11e 4-OCH3 H H - 32 218-222 
11f 4-Cl OCH3 OCH3 - 35 204-208 
17a H - - H 38 158-160 
17b 4-Cl - - H 32 148-152 
17c 4-CF3 - - H 48 126-130 
17d H - - CF3 33 110-114 
 
 
2.2 Molecular modelling 
To investigate the possible binding mode of this series of compounds, we have performed a set 
of molecular docking simulations, using our model of CYP24A124,30. We have previously 
shown the importance of the styrylphenyl structure for inhibitory activity and that the imidazole 
was essential for metal-ligand interaction with the haem group of the enzyme23,24,25. 
Compounds 11a - 11f have electron withdrawing and electron donating substituents on the 
phenyl ring. All compounds were designed without substitution on styrene group except 
compound 11f, which has a 4-Cl on the phenyl ring and 3,4-dimethoxy substitution on the 
styrene group. All the compounds reached the active site through the vitamin D access tunnel 
and interacted with multiple hydrophobic residues (Arg128, Glu130, Ile131, Trp134, Leu148, 
Asn208, Phe212, Ile239, Ile242, Lys243, Met246, Ser247, Phe249, Ala326, Val328, Glu329, 
The330, Val391 and Thr500). Compounds 11b - 11d, formed hydrogen bonds between the 
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nitrogen of the amide group with Leu325. For compound 11e an additional hydrogen bond 
between the methoxy group and Arg128 was observed.  The distance between the imidazole 
ring and the haem iron was between 2.18 Å and 2.58 Å (Table 2). 
 
Table 2. (A) Distance between N of heterocycle of compounds 11a-11f and iron of haem, (B) 
3D, (C) 2D with binding interactions and (D) binding energy (kcal/mol) 
Cpd A B C D 
11a 2.56 Å 
 
 
-8.9 
11b 2.18 Å 
 
 
-7.1 
11c 2.41 Å 
 
 
-7.9 
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Compounds 17a - 17d were modified by changing the position of the alkene group from the 4 to 3-
position. All compound showed good interaction with the active site and interaction between the 
imidazole nitrogen and the iron of the haem with distances ranging between 2.04 Å and 2.29 Å. 
Hydrogen bonds were observed between the amide group, through the C=O and/or NH, and amino acids 
Glu329, Thr330 and Leu325 (Table 3). 
11d 2.42 Å 
 
 
-7.4 
11e 2.58 Å 
 
 
-11.2 
11f 2.44 Å 
 
 
-11.8 
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Table 3. (A) Distance between N of heterocycle of compounds 17a-17d and iron of haem, (B) 
3D, (C) 2D with binding interactions and(D) binding energy (kcal/mol) 
Cpd A B C D 
17a 2.04 Å 
 
 
-11.0 
17b 2.29 Å 
 
 
-10.4 
17c 2.22 Å 
 
 
-7.3 
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2.3 CYP24A1 enzyme inhibition 
All the final compounds 11a - 11f and 17a - 17d were evaluated to determine 
CYP24A1inhibitory activity. The assay was performed according to the method of Zhu et al31 
and in general, the compounds displayed potent inhibition of CYP24A1 activity when 
compared with the ketoconazole standard and the lead  compound 1 (IC50 0.40 μM)24. The IC50 
values ranged between 11 and 35 μM with the best IC50 value was obtained for the 3,4-
dimethoxy styrylbenzamide derivative 11e (0.11 µM) (Table 4). Interestingly, the 4-methoxy 
derivative 11e was also found to interact with the iron of the haem via the methoxy group 
(distance 2.19 Å), which may contribute to the optimal inhibitory activity in this series of 
compounds (Figure 3).       
 
17d 2.28Å 
 
 
-7.6 
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Figure 3. Alternative binding mode of 11e interacting with the iron of the haem through the 
methoxy group 
The unsubstituted 3-styrylbenzamide showed an improvement in inhibitory activity compared with the 
4-styrylbenzamide lead compound 1 (17a IC50 0.19 M compared with lead 1 IC50 0.40 M), whereas 
the 4-chloro (17b/11a) and 4-trifluoromethyl (17c/11b) substituted 3- and 4-styrylbenzamides were 
comparable.  In the 4-styrylbenzamide series substitution at the 2-position of the phenyl ring is less 
favoured e.g. 2-CF3 11c IC50 0.35 M compared with 4-CF3 11b IC50 0.18 M.  
Substitutions in the styryl group would suggest that introduction of substituents at the 3,4-position (11f 
IC50 0.12 M) are beneficial for inhibitory activity and comparable with 3,5-dimethoxy substitution 
(lead 2 IC50 0.11 M), while substitutions in the 2-position are less favourable (17d IC50 0.34 M). 
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Table 4. IC50 data against CYP24A1 of imidazole derivatives 11 and 17 
 
 
Cmpd R R1 R2 IC50 (M) Cmpd R R3 IC50 (M) 
11a 4-Cl H H 0.21 17a H H 0.19 
11b 4-CF3 H H 0.18 17b Cl H 0.16 
11c 2-CF3 H H 0.35 17c CF3 H 0.15 
11d 3,4-diMe H H 0.31 17d H CF3 0.34 
11e 4-OCH3 H H 0.11 Ketoconazole  0.5 
11f 4-Cl OCH3 OCH3 0.12     
Lead 1  H H H 0.40     
 
In general, binding energies (Tables 2 and 3) and IC50 showed a good correlation with the exception of 
compounds 11b and 17c (Fig.4). Substitution of these compounds with the more bulky trifluoromethyl 
group in the para position of the phenyl ring results in a slightly less favourable conformer energy 
compared with the other inhibitors, which affects the overall binding energy. 
 
Figure 4. Correlation between CYP24A1 IC50 and binding energy for imidazole derivatives 11 
and 17 
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3. Conclusions 
A series of 3- and 4-styrylbenzamide imidazole derivatives have been prepared using an 
efficient synthetic route. All the derivatives showed very good inhibitory activity against 
CYP24A1 and, although there were some small differences in IC50 values depending on 
substituents, overall both 3- and 4-styrylbenzamide imidazoles and a range of substituents were 
very well tolerated without any significant loss of inhibitory activity. This inhibitory data 
would agree with the molecular docking where all the compounds fit well within the active site 
and showed a good fill of the hydrophobic channel of the CYP24A1 active site as well as 
transition metal interaction between the iron of the haem and the imidazole ring of the 
derivatives.  
 
4. Experimental 
4.1. Chemistry 
4.1.1. General Experimental 
1,25(OH)2D3 and 25(OH)D3 were purchased from SAFC-Pharma (Madison, WI). Human 
MBP-CYP24A1, bovine adrenodoxin (Adx), and adrenodoxin reductase (AdR) were purified as 
described previously30. All solvents used for chromatography were HPLC grade from Fisher Scientific 
(UK). 1H and 13C NMR spectra were recorded with a Bruker Avance DPX500 spectrometer operating 
at 500 and 125 MHz, with Me4Si as internal standard. Mass spectra and microanalysis were determined 
by MEDAC (Chobham, UK). Flash column chromatography was performed with silica gel 60 (230-
400mesh) (Merck) and TLC was carried out on precoated silica plates (kiesel gel 60 F254, BDH). 
Compounds were visualised by illumination under UV light (254 nm) or by the use of vanillin stain 
followed by charring on a hotplate. Melting points were determined on an electrothermal instrument 
and are uncorrected. All solvents were dried prior to use and stored over 4Å molecular sieves, under 
nitrogen. All compounds were more than 95% pure. 
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4.1.2. General procedure for the preparation of (E)-N-(2-(4-substitued-phenyl)-2-
hydroxyethyl)-4-styrylbenzamides (9) and (E)-N-(2-hydroxy-2-phenylethyl)-3-
styrylbenzamides (15).  
A suspension of (E)-styrylbenzoic acid (8 or 14) (2 mmol) in dry DMF (8 mL) was combined 
with CDI (2.2 mmol). The reaction was stirred for 1 h at room temperature under nitrogen. The 
mixture was cooled to 0 °C then added to a solution of 2-amino-1-phenylethan-1-ol (5) (2 
mmol) in dry DMF (2.5 mL). The resulting mixture was stirred at room temperature overnight 
and on completion, ice was added into the flask and a white solid precipitated out. The 
precipitate was then filtered, washed with ice-cold water and dried. 
4.1.2.1. (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-styrylbenzamide (9a, R = 4-Cl, R1 = 
R2 = H). White crystalline solid obtained after recrystallization from methanol. Yield: 67%; Rf 
0.86 (CH2Cl2-CH3OH 9:1 v/v); mp 258 - 260 °C; 1H NMR (DMSO-d6):  8.52 (t, J = 5.3 Hz, 
1H, NH), 7.85 (d, J = 8.2 Hz, 2H, Ar), 7.73 (d, J = 8.4 Hz, 2H, Ar), 7.74 (d, J = 8.2 Hz, 2H, 
Ar), 7.42 (m, 5H, Ar) 7.24 (m, 4H, Ar), 5.64 (s, 1H, OH), 4.80 (m, 1H, CHOH), 3.49 (m,1H, 
CH2), 3.40 (m, 1H, CH2). 13C NMR (DMSO–d6): 167.6 (CO), 140.9, 137.5, 135.2, 133.6, 
133.2 (5 × C), 129.4, 128.5, 128.1, 127.3, 127.2, 127.1, 126.9 (15 × CH, Ar), 72.2 (CH), 47.1 
(CH2). Anal. Calcd for C23H20ClNO2∙ 0.3H2O (382.52): C 72.08 %, H 5.42 %, N 3.65 %. Found 
C72.20 %, H 5.26 %, N 3.86 %. 
4.1.2.2. (E)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-4-styrylbenzamide (9b, R 
= 4-CF3, R1 = R2 = H). White crystalline solid obtained after recrystallization from methanol. 
Yield: 35%; Rf 0.75 (petroleum ether-EtOAc 3:1 v/v); mp 220 - 224 °C; 1H NMR (DMSO-d6): 
8.58 (t, J = 5.7 Hz, 1H, NH), 7.84 (d, J = 8.4 Hz, 2H, Ar), 7.72 (φt, J = 8.4, 10.5 Hz, 4H, Ar), 
7.65 (m, 4H, Ar), 7.42 (m, 3H, Ar) 7.33 (m, 2H, Ar), 5.77 (d, J = 4.5 Hz, 1H, OH), 4.89 (t, J = 
5.5 Hz, 1H, CHOH), 3.53 (m,1H, CH2), 3.43 (m, 1H, CH2). 13C NMR (DMSO–d6): 166.6 
(CO), 149.0, 140.3, 137.2, 133.6 (4 × C), 129.2, 128.5 (2 × CH, Ar), 128.3, 128.0 (2 × C), 
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127.9, 127.3, 127.2, 127.1, 126.7, 125.4 (13 × CH, Ar), 71.2 (CH), 47.9 (CH2). Anal. Calcd 
for C24H20F3NO2 (411.42): C 70.07 %, H 4.90 %, N 3.40 %. Found C 70.39 %, H 4.79 %, N 
3.47 %. 
4.1.2.3. (E)-N-(2-hydroxy-2-(2-(trifluoromethyl)phenyl)ethyl)-4-styrylbenzamide (9c, R = 
2-CF3, R1 = R2 = H). White crystalline solid obtained after recrystallization from methanol. 
Yield: 58%; Rf 0.40 (petroleum ether-EtOAc 3:1 v/v); mp 160 - 166 °C; 1H NMR (DMSO-d6): 
8.58 (t, J = 6 Hz, 1H, NH), 7.87 (d, J = 8.5 Hz, 3H, Ar), 7.74 (m, 4H, Ar), 7.68 (d, J = 15.5 
Hz, 2H, Ar), 7.51 (t, J = 7.7 Hz, 1H, Ar), 7.42 (m, 2H, Ar) 7.33 (m, 3H, Ar), 5.81 (d, J = 4.0 
Hz, 1H, OH), 5.14 (dd, J = 5.1, 11.9 Hz, 1H, CHOH), 3.51 (m, 2H, CH2). 13C NMR (DMSO–
d6): 169.6 (CO), 141 (C), 140.3, 131.0 (CH), 128.8 (C), 128.2, 128.1, 127.8, 127.3, 127.0, 
126.3, 126.6, 125.1, 126.7, 125.4 (14 × CH, Ar), 124.3, 123.2 (5 × C), 77.2 (CH), 48.3 (CH2). 
Anal. Calcd for C24H20F3NO2 (411.42): C 70.07 %, H 4.90 %, N 3.40 %. Found C 70.22 %, H 
4.92 %, N 3.38 %. 
4.1.2.4. (E)-N-(2-(3,4-dimethylphenyl)-2-hydroxyethyl)-4-styrylbenzamide (9d, R = 3,4-
diCH3, R1 = R2 = H). White crystalline solid obtained after recrystallization from ethanol. 
Yield: 60%; Rf 0.80 (CH2Cl2- CH3OH 9.5:0.5 v/v); mp 150 - 154 °C; 1H NMR (CDCl3): 8.08 
(s, 1H, Ar), 8.63 (d, J = 8.0 Hz, 1H, Ar), 7.57 (d, J = 7.5 Hz, 2H, Ar), 7.42 (t, J = 7.5 Hz, 2H, 
Ar), 7.33 (t, J = 7.5 Hz, 2H, Ar), 7.28 (s, 1H, Ar), 7.26 (s, 1H, Ar) 7.19 (d, J = 4.5 Hz, 2H, Ar), 
7.15 (m, 3H, Ar), 5.88 (t, J = 10.0 Hz, 1H, OH), 4.56 (dd, J = 10.0, 15.0 Hz, 1H, CHOH), 4.17 
(m, 1H, CH2), 3.93 (dd, J = 8.5, 14.5 Hz, 1H, CH2), 3.5 (s, 6H, 2CH3) . 13C NMR (CDCl3): 
166.5 (CO), 142.1, 140.1, 137.3, 134.9, 133.7, 131.6 (6 × C), 130.6, 130.3, 129.2, 128.4, 128.2, 
128.0, 127.8, 127.2, 126.7 (14× C, Ar), 68.6 (CH), 47.4 (CH2), 21.35, 18.71 (2 × CH3). Anal. 
Calcd for C25H25NO2 (371.48): C 80.83 %, H 6.78 %, N 3.77 %. Found C 81.10 %, H 6.78 %, 
N 3.88 % 
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4.1.2.5. (E)-N-(2-hydroxy-2-(4-methoxyphenyl)ethyl)-4-styrylbenzamide (9e, R = 4-
OCH3, R1 = R2 = H). White crystalline solid obtained after recrystallization from methanol. 
Yield: 35%; Rf 0.70 (petroleum ether-EtOAc 1:3 v/v); mp 218 - 220 °C; 1H NMR (DMSO-d6): 
8.50 (t, J = 5.5 Hz, 1H, NH), 7.87 (d, J = 8.3 Hz, 2H, Ar), 7.70 (m, 4H, Ar), 7.65 (m, 3H, 
Ar), 7.33 (m, 2H, Ar), 7.33 (m, 2H, Ar), 6.92 (d, J = 8.3 Hz, 2H), 5.43 (d, J = 4.5 Hz, 1H, OH), 
4.76 (m, 1H, CHOH), 3.74 (s, 3H, OCH3), 3.50 (m,1H, CH2), 3.34 (m, 1H, CH2). 13C NMR 
(DMSO-d6): 166.5 (CO), 158.8, 140.2, 137.3, 136.3, 133.8 (5 × C), 130.6, 129.2, 128.5, 
128.1, 127.6, 127.2, 1114.3 (15 × CH, Ar), 71.2 (CH), 55.4 (OCH3) 48.2 (CH2). Anal. Calcd 
for C24H23NO3 (373.45): C 77.19 %, H 6.21 %, N 3.75 %. Found C 77.32 %, H 6.02 %, N 3.70 
%. 
4.1.2.6. (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-4-(3,4-dimethoxystyryl)benzamide 
(9f, R = 4-Cl, R1 = R2 = OCH3). White crystalline solid obtained after recrystallization from 
acetonitrile. Yield: 69%; Rf 0.20 (petroleum ether-EtOAc 1:1 v/v); mp 168 - 172 °C; 1H NMR 
(DMSO-d6):  8.53 (t, J = 6.0 Hz, 1H, NH), 7.84 (d, J = 8.0 Hz, 2H, Ar), 7.65 (d, J = 8.5 Hz, 
2H, Ar), 7.40 (s, 2H, Ar), 7.36 (m, 2H, Ar), 7.21 (m, 2H, Ar) 7.00 (m, 3H, Ar), 5.66 (d, J = 4.5 
Hz, 1H, OH), 4.81 (m, 1H, CHOH), 3.49 (m,2H, CH2). 13C NMR (DMSO-d6):  166.5 (CO), 
149.5, 149.4, 143.3, 133.2, 131.9, 128.2 (6 × C), 130.7 (CH, Ar), 130.2 (C),128.4, 128.3, 128.2, 
126.3, 125.8, 120.7, 112.3, 109.7 (12 × CH, Ar), 71.0 (CH), 47.3 (CH2). LRMS (ES-TOF) 
m/z: 440 [M37Cl + H]+, 438 [M35Cl  + H]+. HRMS (ES-TOF) Calculated mass: 438.1472 [M + 
H]+, measured mass: 438.1463 [M + H]+ 
4.1.2.7. (E)-N-(2-hydroxy-2-phenylethyl)-3-styrylbenzamide (15a, R = R3 = H). White 
crystalline solid obtained after recrystallization from methanol. Yield: 60%; Rf 0.68 (CH2Cl2-
CH3OH 9:1 v/v); mp 128 - 132 °C; 1H NMR (DMSO-d6): 8.64 (t, J = 6.0 Hz, 1H, NH), 8.11 
(s, 1H, Ar), 7.73 (d, J = 8.0 Hz, 2H, Ar), 7.65 (d, J = 7.5 Hz, 3H, Ar), 7.49 (t, J = 8.0 Hz, 3H, 
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Ar) 7.42 (t, J = 7.5 Hz, 3H, Ar), 7.37 (m, 4H, Ar), 5.64 (s, 1H, OH), 4.80 (m, 1H, CHOH), 3.49 
(m, 1H, CH2), 3.40 (m, 1H, CH2). 13C NMR (DMSO-d6): 166.8 (CO), 144.3, 137.5, 137.3, 
135.5 (4 × C), 129.8, 129.7, 129.3, 129.1, 127.9, 128.5, 128.4, 128.3, 127.5, 127.0, 126.9, 
126.5, (16 × CH, Ar), 71.6 (CH), 48.2 (CH2). Anal. Calcd for C23H21NO2 ∙ 0.4 H2O (350.36): 
C 78.79 %, H 6.27 %, N 3.99 %. Found C 78.35 %, H 6.56 %, N 3.83 %. 
4.1.2.8. (E)-N-(2-(4-chlorophenyl)-2-hydroxyethyl)-3-styrylbenzamide (15b, R = 4-Cl, R3 
= H). Cream crystalline solid obtained after recrystallization from methanol. Yield: 50%; Rf 
0.44 (petroleum ether-EtOAc 2:1 v/v); mp 138 - 142 °C; 1H NMR (DMSO-d6): 8.63 (t, J = 
5.0 Hz, 1H, NH), 8.09 (s, 1H, Ar), 7.63 (d, J = 7.5 Hz, 4H, Ar), 7.48 (t, J = 8.0 Hz, 4H, Ar), 
7.42 (t, J = 7.5 Hz, 3H, Ar) 7.36 (m, 3H, Ar), 5.69 (d, J = 4.0 Hz, 1H, OH), 4.83 (m, 1H, 
CHOH), 3.51 (m, 1H, CH2), 3.39 (m, 1H, CH2). 13C NMR (DMSO-d6): 166.9 (CO), 138.6 
137.5, 135.8, 134.2, 133.2 (5 × C), 131.9, 128.7,128.6, 127.9, 127.3, 127.4,127.1, 126.9, 
126.7,123.4 (15 × CH, Ar), 72.2 (CH), 48.9 (CH2). Anal. Calcd for C24H20ClNO2∙ 0.2 H2O 
(381.47): C 72.42 %, H 5.39 %, N 3.67 %. Found C 72.11 %, H 5.36 %, N 3.77 %. 
4.1.2.9. (E)-N-(2-hydroxy-2-(4-(trifluoromethyl)phenyl)ethyl)-3-styrylbenzamide (15c, R 
= 4-CF3, R3 = H). White crystalline solid obtained after recrystallization from acetonitrile. 
Yield: 31%; Rf 0.52 (petroleum ether-EtOAc 2:1 v/v); mp 184 - 186 °C; 1H NMR (DMSO-d6): 
8.66 (t, J = 5.6 Hz, 1H, NH), 8.08 (s, 1H, Ar), 7.74 (φt, J = 6.6, 7.7 Hz, 4H, Ar), 7.64 (φt, J 
= 8.3, 10.0 Hz, 4H, Ar), 7.49 (t, J = 7.7 Hz, 1H, Ar), 7.42 (t, J = 7.6 Hz, 2H, Ar) 7.33 (m, 3H, 
Ar), 5.80 (d, J = 4.5 Hz, 1H, OH), 4.93 (dd, J = 5.1, 11.9 Hz, 1H, CHOH), 3.54 (m,1H, CH2), 
3.44 (m, 1H, CH2). 13C NMR (DMSO-d6): 166.9 (CO), 149.0, 137.5, 137.2, 135.4 (4 × C), 
129.8, 129.7, 129,2, 129.1 (4 × CH, Ar), 128.3, 128.0 (2 × C), 127.7, 127.3, 127.2,127.1, 
126.8, 125.9 (11 × CH, Ar), 71.2 (CH), 47.9 (CH2). Anal. Calcd for C24H20F3NO2 ∙ 0.1H2O 
(413.23): C 69.76 %, H 4.93 %, N 3.39 %. Found C 69.51%, H 4.94 %, N 3.42 %. 
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4.1.2.10. (E)-N-(2-hydroxy-2-phenylethyl)-3-(2-(trifluoromethyl)styryl)benzamide (15d, 
R = H, R3 = CF3). White solid obtained after purification by flash column chromatography, 
product eluted with petroleum ether-EtOAc 1:1 v/v. Yield: 75%; Rf 0.70 (petroleum ether-
EtOAc 1:1 v/v); mp 88 - 90 °C; 1H NMR (CDCl3): 7.89 (s, 1H, Ar), 7.75 (d, J = 7.7 Hz, 1H, 
Ar), 7.68 (m, 3H, Ar), 7.56 (t, J = 7.7 Hz, 2H, Ar), 7.50 (m, 5H, Ar), 7.41 (t, J = 8 Hz, 1H, Ar), 
7.36 (t, J = 7.7 Hz, 1H, Ar) 7.29 (m, 1H, Ar), 4.97 (dd, J = 3.2, 8.1 Hz, 1H, CHOH), 3.93 (m, 
1H, CH2), 3.55 (m, 1H, CH2). 13C NMR (DMSO-d6): 167.5 (CO), 141.5, 137.3, 136.3 (3 ×C), 
133.6, 129.1, 128.7, 128.4, 127.9, 127.6, 125.7 (14 × CH, Ar), 122.6, 122.2 (2× C), 114.3 (CH, 
Ar), 71.2 (CH), 48.2 (CH2). Anal. Calcd for C24H20F3NO2 (411.42): C 70.07%, H 4.90 %, N 
3.40 %. Found C 69.99 %, H 5.05 %, N 3.53 %. 
4.1.3. General procedure for the preparation of (E)-5-(4-substitued-phenyl)-2-(4-
styrylphenyl)-4,5-dihydrooxazoles (10) and (E)-5-phenyl-2-(3-styrylphenyl)-4,5-
dihydrooxazoles (16).  
A solution of (E)-N-(2-hydroxy-2-phenylethyl)-3/4-styrylbenzamide (9 or 15) (3.4 mmol) in 
dry THF (30 mL) was cooled to 0 °C. Then methansulfonylchloride (2.2 mL, 27 mmol) was 
added and the resulting mixture stirred at 0 °C for 3 h. Triethylamine (6.2 mL, 40.8 mmol) was 
added dropwise and the solution was stirred overnight at room temperature. The mixture was 
quenched by the addition of NH4OH (28 %, 3 mL) and the reaction stirred at room temperature 
for 30 min. Then THF was removed under reduce pressure and the residue was extracted by 
EtOAc (100mL) and water (2 × 100 mL). The organic layer was collected, dried (MgSO4) and 
concentrated under vacuum. The product was pure enough for use in the next reaction. 
4.1.3.1. (E)- 5-(4-chlorophenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (10a, R = 4-Cl, R1 
= R2 = H). Light brown solid obtained. Yield: 40%; Rf 0.47 (CH2Cl2-CH3OH 9:1 v/v); mp 128 
- 130 °C; 1H NMR (DMSO-d6): 7.94 (d, J = 8.3 Hz, 2H, Ar), 7.74 (d, J = 8.3 Hz, 2H, Ar), 
7.66 (d, J = 7.4 Hz, 2H, Ar), 7.48 (d, J = 8.4 Hz, 2H, Ar), 7.42 (m, 5H, Ar), 7.32 (dd, J = 2.6, 
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7.3 Hz, 2H, Ar), 5.82 (dd, J = 3.0, 10.0 Hz, 1H, CH), 4,48 (dd, J = 10, 14.9 Hz, 1H, CH2), 3.85 
(dd, J = 7.4, 15.0 Hz,1H, CH2).  
4.1.3.2. (E)- 2-(4-styrylphenyl)-5-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (10b, R 
= 4-CF3, R1 = R2 = H). Yellow solid obtained. Yield: 90%; Rf 0.70 (petroleum ether-EtOAc 
1:1 v/v); 1H NMR (DMSO-d6): 7.97 (d, J = 8.3 Hz, 2H, Ar), 7.80 (m, 4H, Ar), 7.65 (d, J = 
7.4 Hz, 4H, Ar), 7.61 (d, J = 8.3 Hz, 2H, Ar), 7.34 (m, 3H, Ar), 5.93 (dd, J = 7.4, 10 Hz, 1H, 
CH), 4,53 (dd, J = 10.0, 15 Hz, 1H, CH2), 3.87 (dd, J = 7.2, 1.00 Hz, 1H, CH2).  
4.1.3.3. (E)- 2-(4-styrylphenyl)-5-(2-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (10c, R 
= 2-CF3, R1 = R2 = H). Yellow solid obtained. Yield: 70%; Rf 0.65 (petroleum ether-EtOAc 
1:1 v/v); mp 112 - 118 °C; 1H NMR (DMSO-d6): 8.10 (m, 4H, Ar), 7.89 (m, 3H, Ar), 7.85 
(m, 4H, Ar), 7.82 (d, J = 16.2 Hz, H, alkene), 7.59 (m, 3H, Ar), 5.71 (dd, J = 8.0, 10.1 Hz, 1H, 
CH), 4.51 (dd, J = 10.3, 15.0 Hz, 1H, CH2), 4.01 (dd, J = 8.0, 15.0 Hz, 1H, CH2). 
4.1.3.4. (E)-5-(3,4-dimethylphenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (10d, R = 3,4-
diCH3, R1 = R2 = H). Light brown solid obtained. Yield: 75%; Rf 0.40 (petroleum ether-EtOAc 
1:1 v/v); 1H NMR (DMSO-d6): 7.97 (d, J = 8.3 Hz, 2H, Ar), 7.76 (d, J = 8.3 Hz, 2H, Ar), 
7.66 (d, J = 7.4 Hz, 2H, Ar), 7.42 (t, J = 7.4 Hz, 3H, Ar), 7.36 (s, 1H, Ar), 7.33 (t, J = 7.4 Hz, 
2H, Ar), 7.13 (d, J = 7.4 Hz, 2H, Ar), 5.92 (dd, J = 8.2, 10.1 Hz, 1H, CH), 4.52 (dd, J = 10.3, 
14.9 Hz, 1H, CH2), 3.73 (dd, J = 8.0, 14.9 Hz, 1H, CH2), 2.26 (s, 1H, CH3), 2.24 (s, 1H, CH3). 
4.1.3.5. (E)-5-(4-methoxyphenyl)-2-(4-styrylphenyl)-4,5-dihydrooxazole (10e, R = 4-
OCH3, R1 = R2 = H). Light brown solid obtained. Yield: 90%; Rf 0.55 (petroleum ether-EtOAc 
1:1 v/v); mp 144 - 146 °C;  1H NMR (DMSO-d6): 7.92 (d, J = 8.3 Hz, 2H, Ar), 7.73 (d, J = 
8.3 Hz, 2H, Ar), 7.65 (d, J = 7.5 Hz, 2H, Ar), 7.42 (m, 2H, Ar), 7.34 (m, 5H, Ar), 6.98 (d, J = 
8.3 Hz, 2H, Ar), 5.74 (φt, J = 7.8, 9.8 Hz, 1H, CH), 4.26 (m, 1H, CH2), 4.03 (m, 1H, CH2), 
3.76 (s, 3H, OCH3).  
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4.1.3.6. (E)-5-(3-chlorophenyl)-2-(3-(3,4-dimethoxystyryl)phenyl)-4,5-dihydrooxazole 
(10f, R = 4-Cl, R1 = R2 = OCH3). Light brown solid obtained. Yield: 63%; Rf 0.71 (petroleum 
ether-EtOAc 1:1 v/v); 1H NMR (DMSO-d6): 7.59 (d, J = 8.4 Hz, 3H, Ar), 7.43 (d, J = 7.5 
Hz, 2H, Ar), 7.17 (m, 2H, Ar), 7.15 (m, 3H, Ar), 6.73 (m, 3H, Ar), 5.68 (m, 1H, CH), 4.52 (m, 
1H, CH2), 4.1 (m, 1H, CH2), 3.86 (s, 3H, OCH3), 3.72 (s, 3H, OCH3).  
4.1.3.7. (E)-5-phenyl-2-(3-styrylphenyl)-4,5-dihydrooxazole (16a, R = R3 = H). Cream solid 
obtained. Yield: 85%; Rf 0.55 (petroleum ether-EtOAc 3:1 v/v); 1H NMR (DMSO-d6): 8.01 
(d, J = 7.3 Hz, 2H, Ar), 7.87 (m, 5H, Ar), 7.52 (d, J = 7.3 Hz, 2H, Ar), 7.44 (m, 5H, Ar), 7.38 
(d, 7.3 Hz, 2H, Ar), 5.66 (dd, J = 3.0, 9.7 Hz, 1H, CH), 4.56 (dd, J = 9.7, 15.0 Hz, 1H, CH2), 
4.51 (dd, J = 7.3, 15.0 Hz,1H, CH2).   
4.1.3.8. (E)-5-(4-chlorophenyl)-2-(3-styrylphenyl)-4,5-dihydrooxazole (16b, R = 4-Cl, R3 
= H). Cream solid obtained. Yield: 80%; Rf 0.40 (petroleum ether-EtOAc 1:1 v/v); 1H NMR 
(DMSO-d6): 8.19 (d, J = 8.5 Hz, 2H, Ar), 7.99 (d, 8.5 Hz, 2H, Ar), 7.50 (m, 2H, Ar), 7.41 
(m, 4H, Ar), 7.32 (m, 3H, Ar) 7.18 (m, 3H, Ar), 5.79 (dd, J = 8.2, 10.2 Hz, 1H, CH), 4.50 (dd, 
J = 10.2, 15.3 Hz, 1H, CH2), 4.31 (dd, J = 8.2, 15.3 Hz,1H, CH2).   
4.1.3.9. (E)-2-(3-styrylphenyl)-5-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole (16c, R 
= 4-CF3, R3 = H). Light brown solid obtained. Yield: 92%; Rf 0.57 (petroleum ether-EtOAc 
1:1 v/v); 1H NMR (DMSO-d6): 8.02 (d, J = 8.5 Hz, 2H, Ar), 7.56 (d, J = 8.5 Hz, 2H, Ar), 
7.36 (m, 5H, Ar), 7.17 (m, 3H, Ar), 7.08 (m, 2H, Ar) 7.97 (m, 1H, Ar), 5.51 (dd, J = 10.1, 15.0 
Hz, 1H, CH), 4.09 (dd, J = 8.5, 15.0 Hz, 1H, CH2), 3.99 (dd, J = 8.2, 15.3 Hz,1H, CH2). 
4.1.3.10. (E)-5-phenyl-2-(3-(2-(trifluoromethyl)styryl)phenyl)-4,5-dihydrooxazole (16d, R 
= H, R3 = CF3). Light brown solid obtained. Yield: 56%; Rf 0.60 (petroleum ether-EtOAc 1:1 
v/v); 1H NMR (DMSO-d6): 7.95 (d, J = 8.3 Hz, 2H, Ar), 7.66 (d, J = 8.3 Hz, 2H, Ar), 7.58 
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(d, J = 8.3 Hz, 2H, Ar), 7.52 (d, J = 8.3 Hz, 2H, Ar), 7.32 (m, 7H, Ar), 5.80 (dd, J = 7.7, 10.1 
Hz, 1H, CH), 4.45 (dd, J = 10.1, 14.9 Hz, 1H, CH2), 3.89 (dd, J = 7.5, 14.9 Hz,1H, CH2).  
 
4.1.4. General procedure for the preparation of (E)-N-(2-(1H-imidazol-1-yl)-2-
(phenylethyl)-4-styrylbenzamides (11) and (E)-N-(2-(1H-imidazol-1-yl)-2-(phenylethyl)-
3-styrylbenzamides (17).  
A mixture of (E)-5-(4-chlorophenyl)-2-(3/4-styrylphenyl)-4,5-dihydrooxazole (10 or 16) (3 
mmol) and imidazole (7.4 g, 110 mmol) was refluxed at 125 °C for 48 h. On completion, the 
mixture was extracted between EtOAc (100 mL) and brine (2 × 100 mL). The organic layer 
was dried (MgSO4) and concentrated under vacuum. 
4.1.4.1. (E)-N-(2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-styrylbenzamide (11a, R 
= 4-Cl, R1 = R2 = H). White solid obtained after recrystallization from EtOAc. Yield: 12%; Rf 
0.85 (CH2Cl2-CH3OH 9:1 v/v); mp 238 - 240 °C; 1H NMR (DMSO-d6): 8.73 (t, J = 5.2 Hz, 
1H, NH), 7.86 (s, 1H, imid), 7.77 (d, J = 8.2 Hz, 4H, Ar), 7.68 (d, J = 8.2 Hz, 3H, Ar), 7.64 (d, 
J = 7.5 Hz, 1H, imid), 7.46 (m, 8H, Ar), 6.92 (s, 1H, imid), 5.70 (dd, J = 6.5, 8.2 Hz, 1H, CH), 
4.06 (m, 1H, CH2), 3.44 (m, 1H, CH). 13C NMR (DMSO–d6): 166.8 (CO), 140.5, 
138.7,133.2, 133.1 (5 × C), 137.2, 130.7, 129.3, 129.2, 129.1, 128.5, 127.9,127.1, 126.7, 118.7 
(18 × CH, Ar), 59.1 (CH), 43.7 (CH2). LRMS (ES-TOF) m/z: 430 [M37Cl + H]+, 428 [M35Cl  + 
H]+,  362 [M-imid + H]+. HRMS (ES-TOF) Calculated mass: 428.1523 [M + H]+, measured 
mass: 428.1524 [M + H]+. 
4.1.4.2. (E)-N-(2-(1H-imidazol-1-yl)-2-(4-(trifluoromethyl)phenyl)ethyl)-4 
styrylbenzamide (11b, R = 4-CF3, R1 = R2 = H). Cream solid obtained after recrystallization 
from EtOAc. Yield: 33%; Rf 0.32 (CH2Cl2-CH3OH 9:1 v/v); mp 208 - 210 °C; 1H NMR 
(DMSO-d6): 8.80 (t, J = 5.0 Hz, 1H, NH), 7.91 (s, 1H, imid), 7.78 (dd, J = 3.0, 8.5 Hz, 4H, 
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Ar), 7.69 (d, J = 8.5 Hz, 2H, Ar), 7.64 (d, J = 7.5 Hz, 2H, Ar), 7.60 (s, 1H, imid), 7.42 (m, 4H, 
Ar), 7.32 (m, 3H, Ar), 6.95 (s, 1H, imid), 5.83 (t, J = 7.5 Hz, 1H, CH), 4.13 (m, 12 Hz, 2H, 
CH2).. 13C NMR (DMSO–d6): 166.8 (CO), 144.4, 140.5,137.4, 137.1, 135.4, 133.1 (6 × C), 
130.8, 129.2, 128.5, 128.2, 128.1, 127.9, 127.1,126.7, 126.1, 118.9 (18 × CH, Ar), 59.3 (CH), 
43.7 (CH2). Anal. Calcd for C27H22F3N3O ∙ 0.15H2O (463.87): C 69.86 %, H 4.84 %, N 9.05 
%. Found C 69.56 %, H 4.79 %, N 8.98 %. 
4.1.4.3. (E)-N-(2-(1H-imidazol-1-yl)-2-(2-(trifluoromethyl)phenyl)ethyl)-4 
styrylbenzamide (11c , R = 2-CF3, R1 = R2 = H). Cream solid obtained after recrystallization 
from EtOAc. Yield: 33%; Rf 0.32 (CH2Cl2-CH3OH 9:1 v/v); mp 208 - 210 °C; 1H NMR 
(DMSO-d6): 8.80 (t, J = 5.0 Hz, 1H, NH), 7.91 (s, 1H, imid), 7.78 (dd, J = 3.0, 8.5 Hz, 4H, 
Ar), 7.69 (d, J = 8.5 Hz, 2H, Ar), 7.64 (d, J = 7.5 Hz, 2H, Ar), 7.60 (s, 1H, imid), 7.42 (m, 4H, 
Ar), 7.32 (m, 3H, Ar), 6.95 (s, 1H, imid), 5.83 (t, J = 7.5 Hz, 1H, CH), 4.13 (m, 12 Hz, 2H, 
CH2). 13C NMR (DMSO–d6): 166.8 (CO), 144.4, 140.5, 137.4, 137.1, 135.4, 133.1 (6 × C), 
130.8, 129.2, 128.5, 128.2, 128.1, 127.9, 127.1,126.7, 126.1, 118.9 (18 × CH, Ar), 59.3 (CH), 
43.7 (CH2). Anal. Calcd for C27H22F3N3O ∙ 0.15H2O (463.87): C 69.86 %, H 4.84 %, N 9.05 
%. Found C 69.56 %, H 4.79 %, N 8.98 %. 
4.1.4.4. (E)-N-(2-(3,4-dimethylphenyl)-2-(1H-imidazol-1-yl)ethyl)-4-styrylbenzamide 
(11d, R = 3,4-diCH3, R1 = R2 = H). Yellow solid obtained after recrystallization from EtOAc. 
Yield: 27%; Rf 0.65 (CH2Cl2-CH3OH 9:1 v/v); mp 134 - 136 °C; 1H NMR (DMSO-d6): 8.73 
(t, J = 5.5 Hz, 1H, NH), 7.82 (s, 1H, imid), 7.78 (d, J = 8.5 Hz, 2H, Ar), 7.69 (m, 2H, Ar), 7.41 
(m, 2H, Ar), 7.33 (m, 5H, Ar), 7.18 (s,1H, imid), 7.14 (m, 2H, Ar), 7.02 (s, 1H, imid), 6.89 (s, 
1H, Ar), 5.59 (dd, J = 5.5, 9.0 Hz, 1H, CH), 4.09 (m,1H, CH2), 3.94 (m, 1H, CH2), 2.18 (s, 6H, 
2 x CH3). 13C NMR (DMSO–d6): 167.8 (CO), 157.5, 140.9, 138.7, 137.5, 136.7, 133.4 (6 × 
C), 133.2, 130.7, 129.3, 129.2, 129.1, 128.5, 127.9, 127.1, 126.7, 118.7 (17 × CH, Ar), 59.9 
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(CH), 43.7 (CH2), 25.7 (2 × CH3). LRMS (ES-TOF) m/z: 422 [M + H]+, 214 [M – C6H5-
CH=CH-C6H4-C=O]+. HRMS (ES-TOF) Calculated mass: 422.2251 [M + H]+, measured 
mass: 422.2232 [M + H]+. 
4.1.4.5. (E)-N-(2-(1H-imidazol-1-yl)-2-(4-methoxyphenyl)ethyl)-4-styrylbenzamide (11e, 
R = 4-OCH3, R1 = R2 = H). White solid obtained after recrystallization from EtOAc. Yield: 
32%; Rf 0.41 (CH2Cl2-CH3OH 9:1 v/v); mp 218 - 222 °C; 1H NMR (CDCl3): 8.06 (s, 1H, 
imid), 7.78 (d, J = 7.7 Hz, 2H, Ar), 7.52 (d, J = 7.5 Hz, 2H, Ar), 7.36 (t, J = 7.0 Hz, 2H, Ar), 
7.31 (m, 5H, Ar), 7.24 (d, J = 8 Hz, 2H, Ar), 717 (m, 2H, Ar), 6.94 (d, J = 8.0 Hz, 2H, Ar), 
5.70 (dd, J = 4.0, 9.5 Hz, 1H, CH), 4.34 (m, 1H, CH2), 4.04 (m, 1H, CH), 3.81 (s, 3H, OCH3). 
13C NMR (DMSO–d6): 167.8 (CO), 157.5, 140.9, 138.7, 137.5, 136.7, 133.4 (6 × C), 133.2, 
130.7, 129.3, 129.2, 129.1, 128.5, 127.9, 127.1, 126.7, 118.7 (18 × CH, Ar), 59.9 (CH), 55.1 
(s, 3H, OCH3), 43.7 (CH2). LRMS (ES-TOF) m/z: 424 [M + H]+, 356 [M-imid]+. HRMS (ES-
TOF) Calculated mass: 424.2020 [M + H]+, measured mass: 424.2016 [M + H]+. 
4.1.4.6. (E)-N-(2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(3,4-dimethoxystyryl) 
benzamide (11e, R = 4-Cl, R1 = R2 = OCH3). White solid obtained after recrystallization from 
acetonitrile. Yield: 35%; Rf 0.66 (CH2Cl2-CH3OH 9:1 v/v); mp 204 - 208 °C; 1H NMR 
(DMSO–d6): 8.74 (t, J = 5.4 Hz, 1H, NH), 7.86 (s, 1H, imid), 7.75 (d, J = 8.4 Hz, 2H, Ar), 
7.64 (d, J = 8.4 Hz, 2H, Ar), 7.46 (m, 2H, Ar), 7.37 (s, 1H, imid), 7.32 (s, 2H, Ar), 7.29 (d, J = 
5.1 Hz, 2H, Ar), 7.17 (s, 1H, imid), 7.14 (dd, J = 1.8, 8.4 Hz, 1H, Ar), 6.98 (d, J = 8.4 Hz, 2H, 
Ar), 6.92 (s, 1H, Ar), 5.71 (dd, J = 6.3, 8.7 Hz, 1H, CH), 4.08 (m, 2H, CH2), 3.83 (s, 3H, 
OCH3), 3.78 (s, 3H, OCH3). 13C NMR (DMSO–d6): 166.8 (CO), 149.5, 149.4, 140.9, 138.8 
(4 × C), 137.3 (CH, Ar), 133.2, 132.6 (2 ×C), 130.8 (CH, Ar), 130.1 (C), 129.3, 129.2, 129.1, 
128.1, 126.3, 120.8, 118.7, 112.1, 109.6 (14 × CH, Ar), 59.2 (CH), 43.7 (CH2). LRMS (ES-
TOF) m/z: 490 [ M37Cl + H]+, 488 [M35Cl  + H]+. HRMS (ES-TOF) Calculated mass: 488.1743 
[M + H]+, measured mass: 488.1741 [M + H]+. 
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4.1.4.7. (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-3-styrylbenzamide (17a, R = R3 = H). 
White solid obtained after recrystallization from EtOAc. Yield: 38%; Rf 0.27 (CH2Cl2-CH3OH 
9:1 v/v); mp 158 - 160 °C; 1H NMR (DMSO–d6): 8.82 (t, J = 5.7 Hz, 1H, NH), 7.97 (s, 1H, 
Ar), 7.75 (d, J = 8.0 Hz, 1H, Ar), 7.64 (d, J = 8.0 Hz, 4H, Ar), 7.47 (s, 1H, Ar), 7.42 (m, 7H, 
Ar), 7.35 (m, 4H, Ar), 6.92 (s,1H, imid), 5.71 (dd, J = 6.0, 9.5 Hz, 1H, CH), 4.13 (m,1H, CH2), 
4.02 (m, 1H, CH2). 13C NMR (DMSO–d6): 167.2 (CO), 139.7, 137.6 (2 × C), 137.3 (CH, 
Ar), 137.2, 135.2 (2 × C), 129.9, 129.8, 129.6, 129.2, 128.5, 128.3, 128.1, 127.7, 127.4, 126.7, 
126.3, 125.5, 118.9 (18 × CH, Ar), 59.9 (CH), 43.9 (CH2). Anal. Calcd for C26H23N3O ∙ 0.25 
H2O (397.99): C 78.47 %, H 5.95 %, N 10.56 %. Found C 78.17 %, H 5.95 %, N 10.56. 
4.1.4.8. (E)-N-(2-(4-chlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-3-styrylbenzamide (17b, R 
= 4-Cl, R3 = H). White solid obtained after recrystallization from EtOAc. Yield: 32%; Rf 0.8 
(CH2Cl2-CH3OH 9:1 v/v); mp 148 - 152 °C; 1H NMR (DMSO–d6): 8.82 (t, J = 5.5 Hz, 1H, 
NH), 7.95 (s, 1H, imid), 7.88 (s, 1H, Ar), 7.75 (d, J = 7.5 Hz, 2H, Ar), 7.47 (m, 5H, Ar), 7.31 
(m, 8H, Ar), 6.93 (s, 1H, imid), 5.71 (dd, J = 6.0, 8.5 Hz, 1H, CH), 4.11 (m, 1H, CH), 3.91 
(m,1H, CH2). 13C NMR (DMSO–d6): 167.2 (CO), 138.7, 137.6 (2 × C), 137.2 (CH, Ar), 
137.1, 135.1, 133.2 (3 × C), 129.9, 129.8, 129.4, 192.2, 129.1, 129.0, 128.4, 128.4, 128.1, 
127.1, 126.7, 125.5, 118.8 (17 × CH, Ar), 59.1 (CH), 43.7 (CH2). Anal. Calcd for Calculated 
C26H22ClN3O (427.93): C 72.98 %, H 5.18 %, N 9.81 %. Found C 72.77 %, H 5.36 %, N 9.40. 
4.1.4.9. (E)-N-(2-(1H-imidazol-1-yl)-2-(4-(trifluoromethyl)phenyl)ethyl)-3-
styrylbenzamide (17c, R = 4-CF3, R3 = H). White solid obtained after recrystallization from 
EtOAc. Yield: 48%; Rf 0.6 (CH2Cl2-CH3OH 9:1 v/v); mp 126 - 130 °C; 1H NMR (DMSO–
d6): 8.84 (t, J = 5.5 Hz, 1H, NH), 7.96 (m, 2H, Ar), 7.78 (m, 4H, Ar), 7.64 (m, 5H, Ar), 7.49 
(m, 4H, Ar), 7.33 (m, 2H, Ar), 6.96 (s,1H, imid) 5.84 (m, 1H, CH), 4.15 (m, 2H, CH2). 13C 
NMR (DMSO–d6): 166.9 (CO), 149.0, 144.4, 137.6, 137.5, 135.4, 135.1, 134.9 (7 × C), 
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129.9, 129.8, 129.7, 129.2, 129.1, 128.4, 128.3, 128.2, 128.1, 127.3, 127.0, 126.1, 125.5, 125.4, 
118.9 (18 × CH, Ar), 59.3 (CH), 43.7 (CH2). LRMS (ES-TOF) m/z: 462 [M + H]+, 120 
[C6H5CONH+ + H]+. HRMS (ES-TOF) Calculated mass: 462.1793 [M + H]+, measured mass: 
462.1799 [M + H]+. 
4.1.4.10. (E)-N-(2-(1H-imidazol-1-yl)-2-phenylethyl)-3-(2-(trifluoromethyl)styryl) 
benzamide (17d, R =H, R3 = CF3). White solid obtained after recrystallization from EtOAc. 
Yield: 33%; Rf 0.5 (CH2Cl2-CH3OH 9:1 v/v); mp 110 - 114 °C; 1H NMR (DMSO–d6): 8.87 
(t, J = 5.5 Hz, 1H, NH), 8.02 (d, J = 7.5 Hz, 2H, Ar), 7.86 (s, 1H, IMID), 7.78 (m, 4H, Ar), 
7.54 (m, 5H, Ar), 7.40 (m, 5H, Ar), 6.91 (s,1H, Ar) 5.71 (dd, J = 6.0, 9.0 Hz, 1H, CH), 4.12 
(m, 2H, CH2). 13C NMR (DMSO–d6): 167.9 (CO), 149.0, 144.4, 138.6, 138.5, 136.4, 134.9 
(6 × C), 129.9, 129.8, 129.7, 129.2, 129.1, 128.4, 128.3, 128.2, 128.1, 127.3, 127.0, 126.1, 
125.5, 125.4, 12.4 (18 × CH, Ar), 59.3 (CH), 43.7 (CH2). LRMS (ES-TOF) m/z: 462 [M + H]+, 
394 [M-imidazole]+. HRMS (ES-TOF) Calculated mass: 462.1793 [M + H]+, measured mass: 
462.1795 [M + H]+. 
 
4.2. CYP24A1 inhibition assay  
Inhibition of CYP24A1 was performed as previously described31. Briefly, reaction 
mixture containing 0.1 μM each of Adx and AdR, 0.075 μM MBP-CYP24A1, 2.5 μM 
1,25(OH)2D3, varying concentrations of inhibitors, and 0.5 mM NADPH was incubated at 37 
°C for 25 min in a buffer of 20 mM Tris (pH 7.5) and 125 mM NaCl. All inhibitors were 
dissolved in ethanol (>10 mM) or DMSO (>50 mM) and further diluted in ethanol to make 
working stock (<1 mM). The reaction was extracted with CH2Cl2 and analysed by HPLC. The 
IC50 values were determined by fitting the relative activity (V/V0) against the inhibitor 
concentration [I] using the equation V/V0 = IC50/(IC50 + [I]), where V and V0 are the reaction 
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rates in the presence and absence of inhibitors. The assay for each compound was performed 
in at least duplicate and in triplicate for compounds with good inhibitory properties. 
 
4.3. Molecular modelling 
Docking studies were performed using LeadIT2.1.2 docking program by BioSolve.IT32. The 
important amino acid residues of the active pocket (Gln82, Ile131, Trp134, Met246, Ala326, 
Glu329, Thr330, Val391, Phe393, Thr394, Ser498, Gly499, Tyr500)30 were selected and then 
the selection was extended to 12 Å in order to include in the docking site the haem iron region 
and the access tunnel to the catalytic site. A ligands database in mol2 format, prepared using 
MOE33, was used as input for the docking calculations. The iron atom of the catalytic site was 
set as essential pharmacophoric feature. Ligand docking was performed using the default 
values and no water molecules were considered. Ten output solutions were obtained from each 
compound and visual inspection in MOE was used to identify the interaction between ligand 
and protein.  
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